Literature DB >> 22227519

Ablation of Rassf2 induces bone defects and subsequent haematopoietic anomalies in mice.

Hoogeun Song1, Hyunsoo Kim, Kyunghee Lee, Da-Hye Lee, Tae-Shin Kim, Ji Yun Song, Dongjun Lee, Dongwook Choi, Chang-Yong Ko, Han-Sung Kim, Hong-In Shin, Juhyun Choi, Heedong Park, Chankyu Park, Daewon Jeong, Dae-Sik Lim.   

Abstract

RASSF2 belongs to the Ras-association domain family (RASSF) of proteins, which may be involved in the Hippo signalling pathway. However, the role of RASSF2 in vivo is unknown. Here, we show that Rassf2 knockout mice manifest a multisystemic phenotype including haematopoietic anomalies and defects in bone remodelling. Bone marrow (BM) transplantation showed that Rassf2(-/-) BM cells had a normal haematopoietic reconstitution activity, indicating no intrinsic haematopoietic defects. Notably, in vitro differentiation studies revealed that ablation of Rassf2 suppressed osteoblastogenesis but promoted osteoclastogenesis. Co-culture experiments showed that an intrinsic defect in osteoblast differentiation from Rassf2(-/-) osteoblast precursors likely leads to both haematopoiesis and osteoclast defects in Rassf2(-/-) mice. Moreover, Rassf2 deficiency resulted in hyperactivation of nuclear factor (NF)-κB during both osteoclast and osteoblast differentiation. RASSF2 associated with IκB kinase (IKK) α and β forms, and suppressed IKK activity. Introduction of either RASSF2 or a dominant-negative form of IKK into Rassf2(-/-) osteoclast or osteoblast precursors inhibited NF-κB hyperactivation and normalized osteoclast and osteoblast differentiation. These observations indicate that RASSF2 regulates osteoblast and osteoclast differentiation by inhibiting NF-κB signalling.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22227519      PMCID: PMC3297990          DOI: 10.1038/emboj.2011.480

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  46 in total

1.  The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis.

Authors:  Kwang-Pyo Lee; Joo-Hyeon Lee; Tae-Shin Kim; Tack-Hoon Kim; Hee-Dong Park; Jin-Seok Byun; Min-Chul Kim; Won-Il Jeong; Diego F Calvisi; Jin-Man Kim; Dae-Sik Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

2.  Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression.

Authors:  Hai Song; Kinglun Kingston Mak; Lilia Topol; Kangsun Yun; Jianxin Hu; Lisa Garrett; Yongbin Chen; Ogyi Park; Jia Chang; R Mark Simpson; Cun-Yu Wang; Bin Gao; Jin Jiang; Yingzi Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-08       Impact factor: 11.205

3.  Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver.

Authors:  Li Lu; Ying Li; Soo Mi Kim; Wouter Bossuyt; Pu Liu; Qiong Qiu; Yingdi Wang; Georg Halder; Milton J Finegold; Ju-Seog Lee; Randy L Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

4.  Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity.

Authors:  Hoogeun Song; Sangphil Oh; Hyun Jung Oh; Dae-Sik Lim
Journal:  Biochem Biophys Res Commun       Date:  2009-12-04       Impact factor: 3.575

5.  Crucial role for Mst1 and Mst2 kinases in early embryonic development of the mouse.

Authors:  Sangphil Oh; Dongjun Lee; Tackhoon Kim; Tae-Shin Kim; Hyun Jung Oh; Chae Young Hwang; Young-Yun Kong; Ki-Sun Kwon; Dae-Sik Lim
Journal:  Mol Cell Biol       Date:  2009-09-28       Impact factor: 4.272

6.  Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene.

Authors:  Dawang Zhou; Claudius Conrad; Fan Xia; Ji-Sun Park; Bernhard Payer; Yi Yin; Gregory Y Lauwers; Wolfgang Thasler; Jeannie T Lee; Joseph Avruch; Nabeel Bardeesy
Journal:  Cancer Cell       Date:  2009-11-06       Impact factor: 31.743

7.  Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice.

Authors:  Hyunsoo Kim; Han Kyoung Choi; Ji Hye Shin; Kyung Hee Kim; Ji Young Huh; Seung Ah Lee; Chang-Yong Ko; Han-Sung Kim; Hong-In Shin; Hwa Jeong Lee; Daewon Jeong; Nacksung Kim; Yongwon Choi; Soo Young Lee
Journal:  J Clin Invest       Date:  2009-03-02       Impact factor: 14.808

8.  Mst1-FoxO signaling protects Naïve T lymphocytes from cellular oxidative stress in mice.

Authors:  Juhyun Choi; Sangphil Oh; Dongjun Lee; Hyun Jung Oh; Jik Young Park; Sean Bong Lee; Dae-Sik Lim
Journal:  PLoS One       Date:  2009-11-24       Impact factor: 3.240

9.  Inhibition of osteoblastic bone formation by nuclear factor-kappaB.

Authors:  Jia Chang; Zhuo Wang; Eric Tang; Zhipeng Fan; Laurie McCauley; Renny Franceschi; Kunliang Guan; Paul H Krebsbach; Cun-Yu Wang
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

10.  RASSF2 associates with and stabilizes the proapoptotic kinase MST2.

Authors:  W N Cooper; L B Hesson; D Matallanas; A Dallol; A von Kriegsheim; R Ward; W Kolch; F Latif
Journal:  Oncogene       Date:  2009-06-15       Impact factor: 9.867

View more
  17 in total

1.  Uncovering Adaptation from Sequence Data: Lessons from Genome Resequencing of Four Cattle Breeds.

Authors:  Simon Boitard; Mekki Boussaha; Aurélien Capitan; Dominique Rocha; Bertrand Servin
Journal:  Genetics       Date:  2016-03-26       Impact factor: 4.562

2.  RASSF2 methylation is a strong prognostic marker in younger age patients with Ewing sarcoma.

Authors:  Seley Gharanei; Anna T Brini; Sumathi Vaiyapuri; Abdullah Alholle; Ashraf Dallol; Elena Arrigoni; Takeshi Kishida; Toru Hiruma; Smadar Avigad; Robert Grimer; Eamonn R Maher; Farida Latif
Journal:  Epigenetics       Date:  2013-07-18       Impact factor: 4.528

Review 3.  Tumor suppressor C-RASSF proteins.

Authors:  Hiroaki Iwasa; Shakhawoat Hossain; Yutaka Hata
Journal:  Cell Mol Life Sci       Date:  2018-01-20       Impact factor: 9.261

4.  Tmem64 modulates calcium signaling during RANKL-mediated osteoclast differentiation.

Authors:  Hyunsoo Kim; Taesoo Kim; Byung-Chul Jeong; Il-Taeg Cho; Daehee Han; Noriko Takegahara; Takako Negishi-Koga; Hiroshi Takayanagi; Jae Hee Lee; Jai-Yoon Sul; Vikram Prasad; Seoung Hoon Lee; Yongwon Choi
Journal:  Cell Metab       Date:  2013-02-05       Impact factor: 27.287

Review 5.  Ras signaling through RASSF proteins.

Authors:  Howard Donninger; M Lee Schmidt; Jessica Mezzanotte; Thibaut Barnoud; Geoffrey J Clark
Journal:  Semin Cell Dev Biol       Date:  2016-06-08       Impact factor: 7.727

6.  Targeting bone remodeling by isoflavone and 3,3'-diindolylmethane in the context of prostate cancer bone metastasis.

Authors:  Yiwei Li; Dejuan Kong; Aamir Ahmad; Bin Bao; Fazlul H Sarkar
Journal:  PLoS One       Date:  2012-03-07       Impact factor: 3.240

7.  Loss of RASSF2 Enhances Tumorigencity of Lung Cancer Cells and Confers Resistance to Chemotherapy.

Authors:  Jennifer Clark; Jessica Freeman; Howard Donninger
Journal:  Mol Biol Int       Date:  2012-05-24

8.  Aberrant Promoter Hypermethylation of RASSF Family Members in Merkel Cell Carcinoma.

Authors:  Antje M Richter; Tanja Haag; Sara Walesch; Peter Herrmann-Trost; Wolfgang C Marsch; Heinz Kutzner; Peter Helmbold; Reinhard H Dammann
Journal:  Cancers (Basel)       Date:  2013-11-18       Impact factor: 6.639

Review 9.  A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas.

Authors:  Michael D Deel; Jenny J Li; Lisa E S Crose; Corinne M Linardic
Journal:  Front Oncol       Date:  2015-09-02       Impact factor: 6.244

10.  The tumor suppressor gene, RASSF1A, is essential for protection against inflammation -induced injury.

Authors:  Marilyn Gordon; Mohamed El-Kalla; Yuewen Zhao; Yahya Fiteih; Jennifer Law; Natalia Volodko; Anwar Anwar-Mohamed; Anwar Mohamed; Ayman O S El-Kadi; Lei Liu; Jeff Odenbach; Aducio Thiesen; Christina Onyskiw; Haya Abu Ghazaleh; Jikyoung Park; Sean Bong Lee; Victor C Yu; Carlos Fernandez-Patron; R Todd Alexander; Eytan Wine; Shairaz Baksh
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.